What You Should Know:
– Eko Health, a pioneer in applying artificial intelligence for early detection of heart and lung diseases, today announced the issuance of a Category III Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for its SENSORA™ platform.
-The newly issued Category III CPT code will be effective on July 1, 2025, and is the first step to coverage and reimbursement for SENSORA™, bringing advanced heart disease detection to clinicians across the U.S.
Eko Health: Advancing Early Cardiac Disease Detection with AI-Powered Solutions
Eko Health is a leading digital health company revolutionizing the detection and monitoring of heart and lung diseases through its portfolio of digital stethoscopes, patient and provider software, and AI-driven analytics. The company’s FDA-cleared platform, used by over 500,000 healthcare professionals worldwide, enables earlier and more accurate detection, confident diagnosis, effective treatment management, and ultimately better patient care.
SENSORA: AI-Enhanced Early Disease Detection
SENSORA™ is an advanced platform that empowers clinicians to detect heart disease earlier, featuring FDA-cleared AI algorithms capable of identifying signs of structural heart murmurs, low ejection fraction (Low EF), and arrhythmias such as AFib in front-line care settings. Key features include:
– Seamless integration with the Eko CORE 500™ digital stethoscope, which incorporates advanced ECG technology familiar to every provider.
– The ability to detect cardiac conditions that are often missed by standard care, supporting early intervention and proactive management.
The Critical Role of Early Detection in Heart Disease Management
Heart disease remains the leading cause of death in the United States, responsible for approximately 1 in 5 deaths according to the CDC. Early detection is vital for improving patient outcomes. By equipping primary care providers with the tools to identify cardiac issues at an early stage, SENSORA™ enhances proactive care, reducing the burden of managing advanced heart disease.
Clinical Validation and Impact
Eko’s AI algorithms have been validated in both clinical and real-world studies:
– A clinical trial published in Circulation demonstrated that Eko’s AI for structural heart murmur detection doubled the sensitivity for identifying structural heart disease when compared to traditional analog stethoscopes.
– In a study published in Lancet Digital Health, involving over 1,000 patients, Eko’s low ejection fraction AI accurately detected reduced ejection fraction in primary care settings, leading to its deployment in over 100 clinics in the UK by the NHS and Imperial College London.
Expanding Role in Cardiac Care
SENSORA’s growing significance is further demonstrated by its receipt of the Category III CPT code, which supports its expanding use across various clinical environments. This designation reflects Eko’s dedication to equipping primary care clinicians with AI tools that elevate patient care standards and bridge the gap in preventive care.
“The AMA’s creation of Category III CPT code for Eko’s AI disease detection algorithms is a major step in increasing access to early heart disease detection,” said Connor Landgraf, CEO of Eko Health. “This milestone will help enable clinicians to use powerful, validated tools to identify heart disease early, ultimately improving patient outcomes, especially in communities with limited access to specialist care.”
